Venus Remedies Oncology Wing Expands with GCC, ASEAN, Balkan, and Caribbean Marketing Approvals

Venus Remedies, a global provider of affordable cancer drugs, has strengthened its position in the Gulf Cooperation Council (GCC), Association of South East Asian Nations (ASEAN), Balkan, and Caribbean regions with marketing approvals for key chemotherapy drugs from Oman, Malaysia, Bosnia, and Trinidad and Tobago. With this, the firm has obtained 503 oncology marketing approvals in 75 countries.

While the company has received marketing approval for pemetrexed in Malaysia, one of the largest markets in the ASEAN region, it has also received product registration for docetaxel in Oman, gemcitabine in Bosnia, and carboplatin, bortezomib, and docetaxel in Trinidad and Tobago. "These marketing approvals will enable us to expand our operations to new geographies and open up new avenues for advanced cancer treatment with improved outcomes for patients battling various types of cancer," said Saransh Chaudhary, president, global critical care, Venus Remedies. We remain committed to providing life-saving treatment to an increasing number of patients in accordance with our mission of meeting unmet medical needs in oncology and other critical care segments."

The $2.8 billion Malaysian pharmaceutical market, a growing market for cancer drugs in which Venus Remedies has so far secured marketing approval for 27 products across various segments, presents enormous opportunities for the company to expand its operations in the Asia-Pacific region in general and Southeast Asia in particular through its extensive drug portfolio. "While we have more than 140 marketing authorizations in the ASEAN region, including 147 for oncology drugs," Chaudhary explained, "we are counting on Malaysia's product registration for pemetrexed to pave the way for faster approval of this drug in other ASEAN countries."

Venus Remedies has already submitted dossiers to the Malaysian Health Ministry for another nine marketing authorisations, which include pending approvals for two oncology products. Venus Remedies expects the marketing approval for docetaxel from the US$ 1.4 billion pharmaceutical market in Oman to facilitate the registration process in other Gulf countries as well, considering that many of them have similar regulatory requirements and processes.